Indian Govt's Start-up India campaign to boost innovation in biotech/ pharma sectors

19 January 2016

The Indian government has launched its ambitious Start-up India campaign with the aim to give a leg-up to the investment ecosystem and boost innovation.

The campaign has come as good news for the beginners in the pharma and biotech sector as the multi-point plan now offers government assistance in the face of failure. Further, the government has also promised to provide an easy way out.

The 19-point action plan under the Start-up India campaign not only provides tax waivers but also encourages public private partnership model for 35 new incubators, 31 innovation centers at national institutes and seven research parks, and five new bio-clusters.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK